Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Basic, Translational & Therapy: Radiopharmaceutical Therapy

Metastasis after mTOR inhibition by RAD001 in a neuroendocrine rat tumor model: Combination therapy with 177Lu-DOTA,Tyr3-octreotate

Stefan Pool, Stuart Koelewijn, Eric Krenning and Marion de Jong
Journal of Nuclear Medicine May 2011, 52 (supplement 1) 1746;
Stefan Pool
1Nuclear Medicine, Erasmus MC, Rotterdam, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stuart Koelewijn
1Nuclear Medicine, Erasmus MC, Rotterdam, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Krenning
1Nuclear Medicine, Erasmus MC, Rotterdam, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marion de Jong
1Nuclear Medicine, Erasmus MC, Rotterdam, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Article Information

vol. 52 no. supplement 1 1746

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online November 4, 2014.

Copyright & Usage 
© 2011

Author Information

  1. Stefan Pool1,
  2. Stuart Koelewijn1,
  3. Eric Krenning1 and
  4. Marion de Jong1
  1. 1Nuclear Medicine, Erasmus MC, Rotterdam, Netherlands

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: December 2014 to April 2025

AbstractFullPdf
Dec 2014100
Jan 2015100
May 2015100
Jun 2015300
Jul 2015400
Sep 2015700
Jan 2016100
Mar 2016500
May 2016100
Jun 2016100
Jul 2016200
Aug 2016300
Sep 2016100
Oct 2016300
Nov 2016400
Dec 2016200
Jan 2017100
Feb 2017300
Mar 2017400
May 2017400
Jun 2017200
Sep 2017300
Oct 2017100
Nov 2017300
Dec 2017100
Jan 2018100
Mar 2018800
Apr 2018900
May 2018100
Sep 2018200
Oct 2018100
Nov 2018100
Dec 2018200
Jan 2019200
Feb 2019500
May 2019100
Jun 2019200
Sep 2019100
Nov 2019200
Dec 2019100
Feb 2020600
Mar 20201800
Apr 20201600
May 2020300
Jun 2020100
Jul 2020400
Aug 20201700
Sep 20203000
Oct 20201400
Nov 20202400
Dec 2020800
Jan 2021200
Feb 20211700
Mar 20211000
Apr 20211000
May 2021500
Jun 2021300
Jul 20211500
Aug 20213100
Sep 20211100
Oct 20211000
Nov 20216100
Dec 20213900
Jan 20226100
Feb 20221900
Mar 20221100
Apr 2022500
May 20221900
Jun 2022300
Aug 2022200
Oct 2022100
Nov 2022100
Dec 2022100
Mar 2023200
Apr 2023100
May 2023300
Jun 2023100
Jul 2023300
Aug 2023100
Sep 2023500
Oct 2023400
Nov 2023300
Dec 2023300
Jan 2024300
Feb 2024100
Mar 2024300
Apr 2024200
May 2024200
Jun 2024400
Aug 2024900
Sep 20241100
Oct 2024500
Nov 2024200
Dec 2024400
Feb 2025100
Mar 2025700
Apr 2025500
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 52, Issue supplement 1
May 2011
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Metastasis after mTOR inhibition by RAD001 in a neuroendocrine rat tumor model: Combination therapy with 177Lu-DOTA,Tyr3-octreotate
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Metastasis after mTOR inhibition by RAD001 in a neuroendocrine rat tumor model: Combination therapy with 177Lu-DOTA,Tyr3-octreotate
Stefan Pool, Stuart Koelewijn, Eric Krenning, Marion de Jong
Journal of Nuclear Medicine May 2011, 52 (supplement 1) 1746;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Metastasis after mTOR inhibition by RAD001 in a neuroendocrine rat tumor model: Combination therapy with 177Lu-DOTA,Tyr3-octreotate
Stefan Pool, Stuart Koelewijn, Eric Krenning, Marion de Jong
Journal of Nuclear Medicine May 2011, 52 (supplement 1) 1746;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Basic, Translational & Therapy: Radiopharmaceutical Therapy

  • Urinary excretion of Yttrium-90 following intra-arterial microsphere treatment for liver tumours
  • Characterization of 177Lu-Affibody-HSA bioconjugate for radionuclide therapy of EGFR-expressing head and neck carcinomas
  • Low-dose hyper-radiosensitivity model for 131I radioimmunotherapy of non-Hodgkin’s lymphoma
Show more Oncology: Basic, Translational & Therapy: Radiopharmaceutical Therapy

Radiopharmaceutical Therapy Posters

  • Urinary excretion of Yttrium-90 following intra-arterial microsphere treatment for liver tumours
  • Characterization of 177Lu-Affibody-HSA bioconjugate for radionuclide therapy of EGFR-expressing head and neck carcinomas
  • Low-dose hyper-radiosensitivity model for 131I radioimmunotherapy of non-Hodgkin’s lymphoma
Show more Radiopharmaceutical Therapy Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire